Group 1 - The core point of the article is that Xinhua Medical holds a significant stake in Huajian Medical, which has recently seen a rise in its operations related to stablecoins, potentially benefiting Xinhua Medical's investment returns [1] - Xinhua Medical owns 443.7 million shares of Huajian Medical, representing a 27.29% ownership stake [1] - The financial performance of Huajian Medical will impact Xinhua Medical's investment income due to the equity method of accounting used for this subsidiary [1]

Group 1 - The core point of the article is the relationship between Xinhua Medical and its subsidiary Huajian Medical, specifically regarding ownership and support for business development [1] - Xinhua Medical holds a 27.29% stake in Huajian Medical through its wholly-owned subsidiary Huatuo International Development Co., Ltd [1] - The company respects Huajian Medical's independent decision-making based on its own development strategy and market judgment as a minority shareholder [1] Group 2 - Xinhua Medical will continue to monitor the risks and opportunities in the industry where Huajian Medical operates [1]

Group 1 - The core point of the article is that Xinhua Medical holds a significant stake in Huajian Medical, which has recently seen a rise in its operations related to stablecoins, potentially benefiting Xinhua Medical [1] - Xinhua Medical owns 443.7 million shares of Huajian Medical, representing a 27.29% ownership stake [1] - The company uses the equity method to account for its investment in Huajian Medical, meaning that changes in Huajian Medical's net profit will directly impact Xinhua Medical's investment income [1]

Core Viewpoint - Xinhua Medical (600587) provided information regarding the composition of the board of directors at Huajian Medical, confirming that there are 11 directors in total, with 2 appointed by Xinhua Medical [1] Group 1 - Huajian Medical has a total of 11 board members [1] - Xinhua Medical has appointed 2 directors to the board of Huajian Medical [1]

Core Viewpoint - Xinhua Medical (600587) is actively engaging with investors regarding its stake in Huajian Medical and its support for the company's growth in the medical innovation sector [1] Group 1 - Xinhua Medical holds a 27.29% stake in Huajian Medical through its wholly-owned subsidiary, Huatuo International Development Co., Ltd [1] - The company respects Huajian Medical's independent decision-making based on its development strategy and market judgment as a minority shareholder [1] - Xinhua Medical will continue to monitor the risks and opportunities in the industry where Huajian Medical operates [1]

Core Viewpoint - Xinhua Medical (600587) holds a significant stake in Huajian Medical, which has recently engaged in a strategic partnership with HashKey Exchange to purchase Ethereum, potentially impacting Xinhua Medical's profitability through increased investment income from Huajian Medical's net profit [1] Group 1 - Xinhua Medical indirectly holds 443.7 million shares of Huajian Medical, representing a 27.29% stake [1] - Huajian Medical has established a strategic cooperation with HashKey Exchange, purchasing approximately HKD 149 million worth of Ethereum through its OTC services [1] - As of August 11, Huajian Medical's market capitalization reached HKD 15 billion, valuing Xinhua Medical's stake at HKD 4.1 billion [1] Group 2 - Xinhua Medical states that Huajian Medical is an important associate company, and its net profit will influence Xinhua Medical's investment income through equity method accounting [1]

转自：智通财经 【新华医疗：华检医疗推进医疗创新药RWA交易所生态】智通财经8月18日电，新华医疗在互动平台表 示，华检医疗推进的医疗创新药RWA交易所生态及配套稳定币体系，为业务拓展提供了新的发展思 路，公司未来将持续关注华检医疗所处行业的风险与机遇。 ...

Group 1 - The core viewpoint of the article highlights that Xinhua Medical (600587.SH) is exploring new development ideas through the medical innovation drug RWA exchange ecosystem and its associated stablecoin system promoted by Huajian Medical [1] - The company will continue to pay attention to the risks and opportunities in the industry where Huajian Medical operates [1]

格隆汇8月18日丨新华医疗(600587.SH)在互动平台表示，公司康复机器人系列产品已完成产品设计，现 处于样机研发与试制阶段；公司正有序推进脑机接口技术的前期调研工作。 ...

资金流向方面，今日主力资金净流出3226.26万元，占比成交额10.38%。其中，超大单净流出3200.80万 元、占成交额10.3%，大单净流出25.46万元、占成交额0.08%，中单净流出流入523.46万元、占成交额 1.68%，小单净流入2702.79万元、占成交额8.7%。 通过天眼查大数据分析，山东新华医疗器械股份有限公司共对外投资了54家企业，参与招投标项目5000 次，知识产权方面有商标信息103条，专利信息4360条，此外企业还拥有行政许可347个。 来源：金融界 新华医疗最新一期业绩显示，截至2025一季报，公司营业总收入23.08亿元、同比减少8.74%，归属净利 润1.60亿元，同比减少23.97%，扣非净利润1.58亿元，同比减少24.53%，流动比率1.323、速动比率 0.837、资产负债率46.69%。 天眼查商业履历信息显示，山东新华医疗器械股份有限公司，成立于1993年，位于淄博市，是一家以从 事专用设备制造业为主的企业。企业注册资本60667.7919万人民币，实缴资本17538.5227万人民币。公 司法定代表人为王玉全。 金融界消息 截至2025年8月14日收盘，新华 ...